Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. - Wikidata - wikimedia - TriplyDB

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

http://www.wikidata.org/entity/Q45270618

about

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study Asking the right questions: developing evidence-based strategies for treating HIV in women and children Excluding pregnancy among women initiating antiretroviral therapy: efficacy of a family planning job aid.Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.HIV/AIDS, undernutrition, and food insecurity Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa.Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.Hypersensitivity reactions to HIV therapy.Pharmacogenomics of antimicrobial agents.Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.Least among equals A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons.Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulations Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients.Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.Liver Damage in Patients with HCV/HIV Coinfection Is Linked to HIV-Related Oxidative Stress.Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.Clinical perspectives on human genetic screening to prevent nevirapine toxicity.Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.Adverse effects of highly active antiretroviral therapy in developing countries.Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.

P2860

Q24235724-31664F76-1FFC-44C4-8D59-D10BF9E4F104 Q24246038-36A18282-956A-4975-A51D-745DF58AF667 Q24811445-69977483-8D20-4287-AAA3-2B516A2A06CC Q28743488-81582D49-04D0-4765-B7ED-1EA4D35765D2 Q30494675-455C4014-E50D-4298-9131-38CE63189464 Q30574483-F4C68700-62CD-40BE-81A4-C9EA74ABFDED Q33390898-0BDADC22-7B8E-406B-BB07-8DEC1E0F4613 Q33533366-0E7BFD21-5DCC-4AA6-B913-102475C885AB Q33535469-2F8DC0B1-2DDB-4156-B43D-33213E0CD731 Q33701378-414EDA1E-7121-4DD7-98A0-DA9DFA337863 Q34097961-F3A07D0C-0144-4E4C-A994-A16EDDF16D2A Q34200596-A74E008D-5C9D-4940-97AD-ABD31386DB23 Q34443184-E745A939-4509-475B-9963-10036EB963F4 Q34444338-C5E84723-0D1B-4AC1-ACED-33FE06818E69 Q34472398-FB3F1B7F-8BF7-4652-9417-1634BD577299 Q34687558-67D742FD-6487-4E4D-806B-E9B63C7D32DE Q34973371-D598BA97-8AC3-4B4B-BCD8-B9187F9A099D Q34976463-456DFEF6-A70A-46C4-A5E1-B5DC3AB088CF Q34977413-4D2A066D-AA08-4B00-8B10-BF54F5CF36F9 Q35093189-5A94CE43-E5F6-4001-865D-CF95F09A862B Q35689833-E170A479-FC0A-4153-891D-9D1B36C23EDA Q35771326-7A950790-0A30-4263-B180-18F9C022A526 Q35827891-C570DCCB-09C4-4E69-8CED-71816F08F8C5 Q35855545-EA09125A-D5AC-4247-988C-ED521E6B824F Q36073787-B2764B41-F6E8-4E88-84B0-6D71275B12C6 Q36157703-3EA62708-0CCF-4874-91E5-4B240514BE4E Q36286145-EA7948A4-F776-489D-9A94-9D2B206CA667 Q36402487-673281BE-393F-43B0-99AA-B831E92BEBD8 Q36410952-F4E8265D-CD5D-44D9-AECE-08A140E7E226 Q36422444-A574875E-6331-4D82-A6E5-3F4B487B275D Q36429743-9EA45130-BE4E-4A7E-B51D-1339963FB735 Q36508979-4505B687-FE99-4D11-BC19-FF4504A53255 Q36532141-A1AB9CDF-69B8-430E-928F-AEB410B86EB7 Q36546272-5DA08D23-F19B-4017-ADD5-D40F5FD3F0E6 Q36550813-C313F3EC-F2EB-4B3F-B562-1984A2BE4A74 Q36630680-0F091D67-D705-45C6-9F76-C9FB55A32659 Q36718901-B6195BAD-F6D9-4169-9734-2DEF9E69C6A1 Q36877237-766EF150-C338-4849-8C58-1433F9A7F76C Q36945761-8AA581C9-A4B3-4131-8525-C81483C4C0DC Q36998032-A8078F60-5AA3-459C-9F0B-8EBED1791BD0

P2860

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

http://www.wikidata.org/entity/Q45270618

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@en

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@nl

type

label

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@en

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@nl

prefLabel

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@en

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@nl

P1433

Q45270618-1AB62F24-F13A-485B-892F-CFF9AFD9DDE7

P1476

Q45270618-7884191D-2A6C-46BE-8AC4-713523F63833

P2093

Q45270618-2CEA0213-054A-4A71-A975-40E6A1D12083

Q45270618-397491C5-3194-4397-AF37-E74B3CCBF751

Q45270618-42E99566-D205-4EEE-A63B-90011FED2AE3

Q45270618-8AB20E89-7883-4C82-B338-787B5C9076AB

Q45270618-91FE6064-05DB-46E5-A524-A438236E213C

Q45270618-9A1CA911-27F5-47A0-94D7-0037E7D901C1

Q45270618-9C9386A3-A03F-4C9C-99D7-AAE917067CCD

Q45270618-B3E0D02D-F694-460C-9DF6-CD352918C652

Q45270618-CB61E64D-89E3-4304-88B7-1A7CCCCEC4D6

P304

Q45270618-97F58A71-6ABB-4846-9C72-9EFAF4AF0E85

P31

Q45270618-1FF1552F-8704-45CD-BEC4-1FB80DA44E3E

P356

Q45270618-84211CB3-8F35-4C72-B0B5-CA5C4DA25289

P407

Q45270618-8B6AAE32-F360-44D1-AC04-350887EEED3E

P433

Q45270618-70B0EF8F-D800-4D61-B425-83552BD68DB2

P478

Q45270618-563688E3-E9FF-4F1C-91A4-319A6386E957

P50

Q45270618-0CEFDBD5-7CE0-419D-9271-5E5DE8B06549

Q45270618-CD5266E1-0CB8-4126-9EEF-ED1A6B219986

P577

Q45270618-22D6DA02-4CA5-4176-A0EC-2EB78918F1A4

P5875

Q45270618-A6C95797-F916-43E4-AEC2-FEB81281D0CB

P698

Q45270618-97EE0AE0-75D8-4E20-8E4C-F0FE0D05E06D

P921

Q45270618-33A07E8A-5C2C-4932-BA97-ECE5B664D5F1

P356

P1433

The Journal of Infectious Diseases

P1476

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

@en

P2093

Audrey Shaw

http://www.w3.org/2001/XMLSchema#string

Charles Wakeford

http://www.w3.org/2001/XMLSchema#string

Franck Rousseau

http://www.w3.org/2001/XMLSchema#string

Herve Mommeja-Marin

http://www.w3.org/2001/XMLSchema#string

Ian Sanne

http://www.w3.org/2001/XMLSchema#string

John A Bartlett

http://www.w3.org/2001/XMLSchema#string

John Hinkle

http://www.w3.org/2001/XMLSchema#string

Joseph Quinn

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

P304

825-829

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/428093

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

191

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-02-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8016459

http://www.w3.org/2001/XMLSchema#string

P698

15717255

http://www.w3.org/2001/XMLSchema#string

P921